PTC Therapeutics, Inc.
PTCT Healthcare Biotechnology
PTC Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.7 billion, up 114.5% from fiscal 2024. In the quarter to June 2026, revenue grew 101.6%, EPS grew 221.7%, free cash flow grew 295.7% and total debt rose 21.6%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow PTCT
PTC Therapeutics, Inc. (PTCT) Altman Z-score
PTC Therapeutics, Inc.'s Altman Z-score for fiscal 2025 is 1.86, in the grey zone (1.81–2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 1.86 | 3.67 |
| FY2024 | −1.81 | 0.04 |
| FY2023 | −1.85 | (0.22) |
| FY2022 | −1.63 | (0.90) |
| FY2021 | −0.73 | (1.14) |
| FY2020 | 0.41 | (0.31) |
| FY2019 | 0.72 | 0.59 |
| FY2018 | 0.13 | 0.91 |
| FY2017 | −0.78 | 1.92 |
| FY2016 | −2.70 | (4.73) |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.45 | — | 0.54 | |
| Retained earnings / total assets | (1.02) | — | −1.43 | |
| EBIT / total assets | 0.30 | — | 0.99 | |
| Market value of equity / total liabilities | 1.95 | — | 1.17 | |
| Sales / total assets | 0.60 | — | 0.60 | |
| Altman Z-score | Grey zone | 1.86 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Grey zone | 1.56 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| CGON CG Oncology, Inc. compare | 49.0× |
| CRSP CRISPR Therapeutics AG compare | 7.0× |
| MIRM Mirum Pharmaceuticals, Inc. compare | 4.4× |
| COGT Cogent Biosciences, Inc. compare | 3.5× |
| PTCT PTC Therapeutics, Inc. | 1.9× |
| TVTX Travere Therapeutics, Inc. compare | 1.8× |
| SRRK Scholar Rock Holding Corporation compare | 1.1× |
| ORKA Oruka Therapeutics, Inc. compare | — |
| ERAS Erasca, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets